It may be hard to predict what the elimination of the “safe harbor” that has allowed for prescription drug rebates in the US will mean for participants in the pharmaceutical supply chain, but the release of the rule makes one thing very clear: HHS Secretary Alex Azar intends to lead the drug pricing debate in 2019.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?